ImmunoCellular Therapeutics

OverviewSuggest Edit

ImmunoCellular Therapeutics is a clinical-stage biotechnology company developing immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell immunotherapy targeting cancer stem cells and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme. The Company is also developing a portfolio of other potential therapeutic immunotherapies to treat various types of cancer.

TypePublic
Founded2006
HQCalabasas, US
Websiteimuc.com

Latest Updates

Employees (est.) (Feb 2019)3(-57%)
Revenue (FY, 2017)$0
Share Price (Nov 2020)$0.3
Cybersecurity ratingAMore

Key People/Management at ImmunoCellular Therapeutics

Anthony Gringery

Anthony Gringery

President and Chief Executive Officer
John S. Yu

John S. Yu

Founder
Gary S. Titus

Gary S. Titus

Chairman
Show more

ImmunoCellular Therapeutics Office Locations

ImmunoCellular Therapeutics has an office in Calabasas
Calabasas, US (HQ)
23622 Calabasas Rd #300
Show all (1)

ImmunoCellular Therapeutics Financials and Metrics

ImmunoCellular Therapeutics Revenue

USD

Net income (Q2, 2018)

(306.7k)

EBIT (Q2, 2018)

(307.1k)

Market capitalization (24-Nov-2020)

1.3m

Closing stock price (24-Nov-2020)

0.3

Cash (30-Jun-2018)

2.9m
ImmunoCellular Therapeutics's current market capitalization is $1.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

General and administrative expense

2.4m3.6m3.4m3.2m4.6m5.0m4.0m

R&D expense

5.0m7.7m5.3m6.0m10.9m19.1m17.1m

Operating expense total

7.4m11.3m8.7m9.2m15.5m24.1m21.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

General and administrative expense

579.9k634.2k805.8k837.3k1.0m769.3k788.4k985.1k865.4k838.2k786.7k896.7k926.6k908.1k1.1m1.0m908.4k793.2k988.3k1.1m734.6k670.2k

R&D expense

858.2k1.2m2.0m2.2m2.4m1.4m1.2m1.3m1.7m1.5m1.5m2.0m2.2m2.6m4.7m4.4m4.6m4.7m10.4m2.8m290.6k59.0k

Operating expense total

1.4m1.9m2.8m3.0m3.4m2.2m2.0m2.3m2.6m2.3m2.3m2.9m3.2m3.5m5.8m5.5m5.5m5.5m11.3m3.9m1.0m729.2k
USDQ2, 2011

Financial Leverage

2.7 x
Show all financial metrics

ImmunoCellular Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

ImmunoCellular Therapeutics Online and Social Media Presence

Embed Graph

ImmunoCellular Therapeutics News and Updates

ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

LOS ANGELES, Oct. 15, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today notified the NYSE American of its intention to voluntarily withdraw its Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS)...

ImmunoCellular Therapeutics Blogs

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

-Ongoing Exploration of Strategic Opportunities- -Continued Progress in Stem-to-T-Cell Program- LOS ANGELES , Aug. 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer

ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit

Settlement Will Be Paid By Company's Insurance Carrier LOS ANGELES , July 19, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell

ImmunoCellular Therapeutics Frequently Asked Questions

  • When was ImmunoCellular Therapeutics founded?

    ImmunoCellular Therapeutics was founded in 2006.

  • Who are ImmunoCellular Therapeutics key executives?

    ImmunoCellular Therapeutics's key executives are Anthony Gringery, John S. Yu and Gary S. Titus.

  • How many employees does ImmunoCellular Therapeutics have?

    ImmunoCellular Therapeutics has 3 employees.

  • Who are ImmunoCellular Therapeutics competitors?

    Competitors of ImmunoCellular Therapeutics include Biop Medical, MiracleCord and Therapeia.

  • Where is ImmunoCellular Therapeutics headquarters?

    ImmunoCellular Therapeutics headquarters is located at 23622 Calabasas Rd #300, Calabasas.

  • Where are ImmunoCellular Therapeutics offices?

    ImmunoCellular Therapeutics has an office in Calabasas.

  • How many offices does ImmunoCellular Therapeutics have?

    ImmunoCellular Therapeutics has 1 office.